Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: A Children's Cancer Group report

Mark A. Lones, Sherrie L. Perkins, Richard Sposto, Nicole Tedeschi, Marshall E. Kadin, Carl R. Kjeldsberg, John F. Wilson, David L. Zwick, Mitchell S. Cairo

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Purpose: Non-Hodgkin's lymphoma (NHL) arising in bone is a heterogeneous histologic type of NHL that includes large-cell lymphoma, lymphoblastic lymphoma, and small noncleaved-cell lymphoma. NHL arising in bone is well recognized in adults but is less well characterized and infrequent in children and adolescents. Patients and Methods: We performed a retrospective review of Children's Cancer Group (CCG) studies treating children and adolescents with NHL over a 20-year period (CCG-551, CCG-501, CCG-502, CCG-503, CCG-552, CCG-5911, and CCG-5941) and determined the response and event-free survival (EFS) rates in 31 patients with NHL arising in bone. Results: The patients ranged in age from 3 to 17 years (median, 11 years; mean, 11 years), and 64.5% were male. All 31 (100%) patients achieved complete response. For 31 patients with NHL arising in bone, the product-limit estimated 5-year EFS was 83.8% ± 6.7%. EFS in 17 patients with localized disease (Murphy stages I and II) was 94.1% ± 5.7%, and EFS in 14 patients with disseminated disease (Murphy stage III) was 70.7% ± 12.4% (log-rank P = .10). EFS in 17 patients treated with chemotherapy and radiation was 70.1% ± 11.2%, and EFS in 14 patients treated with chemotherapy without radiation was 100% (P = .03). EFS in 26 patients with histology-directed treatment (LSA2-L2 or ADCOMP for lymphoblastic, other therapy for nonlymphoblastic) was 92.2% ± 5.3%, and in five patients with nonhistology-directed treatment it was 40.0% ± 21.9% (P < .001). Conclusion: NHL arising in bone is a heterogeneous type of NHL that makes up approximately 2.0% of NHL in children and adolescents on CCG studies. Response and survival in this young age group seem superb, with histology-directed treatment protocols without radiation in both localized and disseminated disease.

Original languageEnglish (US)
Pages (from-to)2293-2301
Number of pages9
JournalJournal of Clinical Oncology
Volume20
Issue number9
DOIs
StatePublished - May 1 2002

Fingerprint

Non-Hodgkin's Lymphoma
Bone and Bones
Disease-Free Survival
Neoplasms
Radiation
Histology
Drug Therapy
Clinical Protocols
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma
Therapeutics
Survival Rate
Age Groups
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome : A Children's Cancer Group report. / Lones, Mark A.; Perkins, Sherrie L.; Sposto, Richard; Tedeschi, Nicole; Kadin, Marshall E.; Kjeldsberg, Carl R.; Wilson, John F.; Zwick, David L.; Cairo, Mitchell S.

In: Journal of Clinical Oncology, Vol. 20, No. 9, 01.05.2002, p. 2293-2301.

Research output: Contribution to journalArticle

Lones, Mark A. ; Perkins, Sherrie L. ; Sposto, Richard ; Tedeschi, Nicole ; Kadin, Marshall E. ; Kjeldsberg, Carl R. ; Wilson, John F. ; Zwick, David L. ; Cairo, Mitchell S. / Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome : A Children's Cancer Group report. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 9. pp. 2293-2301.
@article{400e85b8fc68441ca4a2d6821455e8bc,
title = "Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: A Children's Cancer Group report",
abstract = "Purpose: Non-Hodgkin's lymphoma (NHL) arising in bone is a heterogeneous histologic type of NHL that includes large-cell lymphoma, lymphoblastic lymphoma, and small noncleaved-cell lymphoma. NHL arising in bone is well recognized in adults but is less well characterized and infrequent in children and adolescents. Patients and Methods: We performed a retrospective review of Children's Cancer Group (CCG) studies treating children and adolescents with NHL over a 20-year period (CCG-551, CCG-501, CCG-502, CCG-503, CCG-552, CCG-5911, and CCG-5941) and determined the response and event-free survival (EFS) rates in 31 patients with NHL arising in bone. Results: The patients ranged in age from 3 to 17 years (median, 11 years; mean, 11 years), and 64.5{\%} were male. All 31 (100{\%}) patients achieved complete response. For 31 patients with NHL arising in bone, the product-limit estimated 5-year EFS was 83.8{\%} ± 6.7{\%}. EFS in 17 patients with localized disease (Murphy stages I and II) was 94.1{\%} ± 5.7{\%}, and EFS in 14 patients with disseminated disease (Murphy stage III) was 70.7{\%} ± 12.4{\%} (log-rank P = .10). EFS in 17 patients treated with chemotherapy and radiation was 70.1{\%} ± 11.2{\%}, and EFS in 14 patients treated with chemotherapy without radiation was 100{\%} (P = .03). EFS in 26 patients with histology-directed treatment (LSA2-L2 or ADCOMP for lymphoblastic, other therapy for nonlymphoblastic) was 92.2{\%} ± 5.3{\%}, and in five patients with nonhistology-directed treatment it was 40.0{\%} ± 21.9{\%} (P < .001). Conclusion: NHL arising in bone is a heterogeneous type of NHL that makes up approximately 2.0{\%} of NHL in children and adolescents on CCG studies. Response and survival in this young age group seem superb, with histology-directed treatment protocols without radiation in both localized and disseminated disease.",
author = "Lones, {Mark A.} and Perkins, {Sherrie L.} and Richard Sposto and Nicole Tedeschi and Kadin, {Marshall E.} and Kjeldsberg, {Carl R.} and Wilson, {John F.} and Zwick, {David L.} and Cairo, {Mitchell S.}",
year = "2002",
month = "5",
day = "1",
doi = "10.1200/JCO.2002.06.017",
language = "English (US)",
volume = "20",
pages = "2293--2301",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome

T2 - A Children's Cancer Group report

AU - Lones, Mark A.

AU - Perkins, Sherrie L.

AU - Sposto, Richard

AU - Tedeschi, Nicole

AU - Kadin, Marshall E.

AU - Kjeldsberg, Carl R.

AU - Wilson, John F.

AU - Zwick, David L.

AU - Cairo, Mitchell S.

PY - 2002/5/1

Y1 - 2002/5/1

N2 - Purpose: Non-Hodgkin's lymphoma (NHL) arising in bone is a heterogeneous histologic type of NHL that includes large-cell lymphoma, lymphoblastic lymphoma, and small noncleaved-cell lymphoma. NHL arising in bone is well recognized in adults but is less well characterized and infrequent in children and adolescents. Patients and Methods: We performed a retrospective review of Children's Cancer Group (CCG) studies treating children and adolescents with NHL over a 20-year period (CCG-551, CCG-501, CCG-502, CCG-503, CCG-552, CCG-5911, and CCG-5941) and determined the response and event-free survival (EFS) rates in 31 patients with NHL arising in bone. Results: The patients ranged in age from 3 to 17 years (median, 11 years; mean, 11 years), and 64.5% were male. All 31 (100%) patients achieved complete response. For 31 patients with NHL arising in bone, the product-limit estimated 5-year EFS was 83.8% ± 6.7%. EFS in 17 patients with localized disease (Murphy stages I and II) was 94.1% ± 5.7%, and EFS in 14 patients with disseminated disease (Murphy stage III) was 70.7% ± 12.4% (log-rank P = .10). EFS in 17 patients treated with chemotherapy and radiation was 70.1% ± 11.2%, and EFS in 14 patients treated with chemotherapy without radiation was 100% (P = .03). EFS in 26 patients with histology-directed treatment (LSA2-L2 or ADCOMP for lymphoblastic, other therapy for nonlymphoblastic) was 92.2% ± 5.3%, and in five patients with nonhistology-directed treatment it was 40.0% ± 21.9% (P < .001). Conclusion: NHL arising in bone is a heterogeneous type of NHL that makes up approximately 2.0% of NHL in children and adolescents on CCG studies. Response and survival in this young age group seem superb, with histology-directed treatment protocols without radiation in both localized and disseminated disease.

AB - Purpose: Non-Hodgkin's lymphoma (NHL) arising in bone is a heterogeneous histologic type of NHL that includes large-cell lymphoma, lymphoblastic lymphoma, and small noncleaved-cell lymphoma. NHL arising in bone is well recognized in adults but is less well characterized and infrequent in children and adolescents. Patients and Methods: We performed a retrospective review of Children's Cancer Group (CCG) studies treating children and adolescents with NHL over a 20-year period (CCG-551, CCG-501, CCG-502, CCG-503, CCG-552, CCG-5911, and CCG-5941) and determined the response and event-free survival (EFS) rates in 31 patients with NHL arising in bone. Results: The patients ranged in age from 3 to 17 years (median, 11 years; mean, 11 years), and 64.5% were male. All 31 (100%) patients achieved complete response. For 31 patients with NHL arising in bone, the product-limit estimated 5-year EFS was 83.8% ± 6.7%. EFS in 17 patients with localized disease (Murphy stages I and II) was 94.1% ± 5.7%, and EFS in 14 patients with disseminated disease (Murphy stage III) was 70.7% ± 12.4% (log-rank P = .10). EFS in 17 patients treated with chemotherapy and radiation was 70.1% ± 11.2%, and EFS in 14 patients treated with chemotherapy without radiation was 100% (P = .03). EFS in 26 patients with histology-directed treatment (LSA2-L2 or ADCOMP for lymphoblastic, other therapy for nonlymphoblastic) was 92.2% ± 5.3%, and in five patients with nonhistology-directed treatment it was 40.0% ± 21.9% (P < .001). Conclusion: NHL arising in bone is a heterogeneous type of NHL that makes up approximately 2.0% of NHL in children and adolescents on CCG studies. Response and survival in this young age group seem superb, with histology-directed treatment protocols without radiation in both localized and disseminated disease.

UR - http://www.scopus.com/inward/record.url?scp=0036570070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036570070&partnerID=8YFLogxK

U2 - 10.1200/JCO.2002.06.017

DO - 10.1200/JCO.2002.06.017

M3 - Article

C2 - 11981000

AN - SCOPUS:0036570070

VL - 20

SP - 2293

EP - 2301

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -